Kasagi K, Hidaka A, Nakamura H, Takeuchi R, Misaki T, Iida Y, Konishi J
Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
J Clin Endocrinol Metab. 1993 Feb;76(2):504-8. doi: 10.1210/jcem.76.2.8094394.
To clarify the relation of TSH receptor antibody (TRAb) to Graves' ophthalmopathy and thyroid function, the activities of TSH binding inhibitor immunoglobulins, thyroid-stimulating antibodies, and thyroid stimulation-blocking antibodies were measured in five patients with hypothyroid Graves' disease. The diagnosis was based on the presence of Graves' ophthalmopathy and either permanent or transient hypothyroidism without a history of treatment for hyperthyroid Graves' disease. TSH binding inhibitor immunoglobulins and thyroid-stimulating antibodies were detected in all five patients. Thyroid stimulation-blocking antibodies results indicated that a blocking type of TRAb was not a cause of hypothyroidism. Destructive changes in the thyroid were probably responsible for hypothyroidism, since 1) high antibody titers against thyroglobulin and thyroid microsomal antigen, 2) diffuse hypoechogenicity of the thyroid on ultrasonography, 3) absent or impaired responses of serum T3 after TRH or TSH stimulation, and 4) histological findings similar to those in Hashimoto's thyroiditis were observed. In all patients except one, thyroid function was changeable, with euthyroid and even subclinical hyperthyroid episodes occurring during the course of the illness. It is conceivable that such unstable thyroid function may be attributable to subtle changes in the balance between the effects of destructive changes in the thyroid and the stimulatory effects of TRAb. In conclusion, all patients had TRAb, suggesting a possible relationship between such antibodies and Graves' ophthalmopathy. Patients develop euthyroidism or subclinical hyperthyroidism during the course of the illness with high frequency.
为阐明促甲状腺激素受体抗体(TRAb)与格雷夫斯眼病及甲状腺功能之间的关系,我们检测了5例甲状腺功能减退型格雷夫斯病患者的促甲状腺激素结合抑制性免疫球蛋白、促甲状腺抗体及甲状腺刺激阻断抗体的活性。诊断依据为存在格雷夫斯眼病以及永久性或暂时性甲状腺功能减退,且无甲状腺功能亢进型格雷夫斯病治疗史。所有5例患者均检测到促甲状腺激素结合抑制性免疫球蛋白和促甲状腺抗体。甲状腺刺激阻断抗体检测结果表明,阻断型TRAb并非甲状腺功能减退的病因。甲状腺的破坏性改变可能是甲状腺功能减退的原因,因为观察到:1)抗甲状腺球蛋白和甲状腺微粒体抗原的抗体滴度较高;2)超声检查显示甲状腺弥漫性低回声;3)促甲状腺激素释放激素(TRH)或促甲状腺激素(TSH)刺激后血清三碘甲状腺原氨酸(T3)反应缺失或受损;4)组织学表现与桥本甲状腺炎相似。除1例患者外,所有患者的甲状腺功能均不稳定,在病程中出现甲状腺功能正常甚至亚临床甲状腺功能亢进发作。可以想象,这种不稳定的甲状腺功能可能归因于甲状腺破坏性改变的影响与TRAb刺激作用之间平衡的细微变化。总之,所有患者均存在TRAb,提示此类抗体与格雷夫斯眼病之间可能存在关联。患者在病程中频繁出现甲状腺功能正常或亚临床甲状腺功能亢进。